CEA Tumor Marker Test Cost and Medicare Coverage (CPT 82378)

Also called: carcinoembryonic antigen · CEA blood test · CEA level · CEA tumor marker — all the same test, CPT 82378.

The short answer

Covered for following a cancer that is already diagnosed, mainly colorectal cancer, and only at the points where the result would change treatment. Medicare’s national policy (NCD 190.26, the same in every state) says CEA “may be medically necessary for follow-up of patients with colorectal carcinoma,” and then narrows that: “It would however only be medically necessary at treatment decision-making points.” The policy also covers CEA as an alternative marker for some other cancers when the tumor does not make a more specific one, as a preoperative level before surgery, and for tracking a metastatic tumor’s response to treatment.

The policy’s limitations are about frequency: generally not more often than once per chemotherapy cycle, or every two months after colorectal cancer surgery, with room for more when something has changed. And it is not a screening test. MedlinePlus says plainly that “CEA tests are not used to screen for or diagnose cancer,” Cleveland Clinic says “providers don’t use it to screen for cancer,” and both Quest and Labcorp say the same in their directories. Medicare’s policy never uses the word screening, and every situation it covers presupposes a cancer that is already known. The colorectal screening test Medicare does cover, the fecal occult blood test, has its own page and its own rules.

When Medicare DOES cover it

The national policy’s covered picture, in plain English:

• Follow-up of colorectal cancer, at treatment decision points. The policy’s own words: medically necessary “for follow-up of patients with colorectal carcinoma,” but “only medically necessary at treatment decision-making points.”
• After treatment for colorectal cancer, on a schedule. The policy cites an ASCO guideline: “if resection of liver metastasis would be indicated, it is recommended that post-operative CEA testing be performed every two to three months in patients with initial stage II or stage III disease for at least two years after diagnosis.”
• As an alternative marker for certain other cancers. The policy’s examples are “adenocarcinoma of the lung, small cell carcinoma of the lung, and some gastrointestinal carcinomas,” in situations “when a more specific marker is not expressed by the tumor.”
• Before surgery. “Preoperative CEA may also be helpful in determining the post-operative adequacy of surgical resection and subsequent medical management.”
• A metastatic tumor that makes CEA. “CEA may be measured at the start of the treatment and with subsequent treatment cycles to assess the tumor’s response to therapy.”

The policy adds that “in general, a single tumor marker will suffice in following patients with colorectal carcinoma or other malignancies that express such tumor markers.” If one of these genuinely describes your situation, the diagnosis for it belongs on your doctor’s order, and coverage follows.

When Medicare does NOT cover it

• CEA as a cancer check in someone with no cancer diagnosis. The policy has no covered indication for it; every covered use starts from a carcinoma that is already known. Quest’s directory says “CEA levels are not useful in screening the general population for undetected cancers,” and Labcorp’s says “CEA determinations are not recommended for cancer screening in the general population.”
• More often than the policy’s schedule. CEA is “generally not indicated more frequently than once per chemotherapy treatment cycle for patients with metastatic solid tumors which express CEA or every two months post-surgical treatment for patients who have had colorectal carcinoma.” The policy does allow more frequent testing “in certain situation, for example, when there has been a significant change from prior CEA level or a significant change in patient status which could reflect disease progression or recurrence.”
• Repeats for an in situ carcinoma. “Testing with a diagnosis of an in situ carcinoma is not reasonably done more frequently than once, unless the result is abnormal, in which case the test may be repeated once.”
• A second tumor marker alongside CEA when one would do. The policy says a single marker “will suffice.”

(Never ask anyone to change a code just to get coverage; that is fraud. But doctors often have a legitimate reason for the test that simply wasn’t written down.)

What you pay if it IS covered: $0

Covered lab tests cost Medicare patients nothing, with no deductible and no 20% coinsurance. Medicare pays the lab $18.96 for a CEA test, and you owe zero.

What you pay if it is NOT covered, read this before you sign

Quest’s own test directory flags CEA as “subject to a Medicare Limited Coverage Policy” that “may require a signed ABN when ordering.” (Labcorp’s page carries no such notice.) If CEA is on your order without a cancer diagnosis behind it, or sooner than the policy’s schedule allows, expect the Advance Beneficiary Notice (ABN), the signature pad, committing you to the lab’s own billing rates if Medicare denies the claim. Before you sign:

1. Ask the lab to print exactly what you would owe. You’re entitled to see the number in black and white first. For perspective: when Medicare covers this exact test, it pays the lab $18.96.
2. Ask when your last CEA was drawn. The policy’s limits are counted in chemotherapy cycles and in months after surgery, so the date of the last one is part of whether this one is covered.
3. Know the direct prices: a CEA test sells for about $42.90 all in at Ulta Lab Tests (partner link in the table; our commission is disclosed there) and $48.00 all in at Jason Health (jasonhealth.com, including their flat $18 lab-collection fee per order). Quest’s consumer site, Labcorp OnDemand, and Personalabs do not sell it. Same certified labs, same blood draw.

Before you sign the pad, 60-second checklist

1. Ask: “Can you print what I’ll owe if Medicare doesn’t pay?”
2. Ask your doctor: “Is this to follow a cancer already on my chart, is it at a decision point, and is that diagnosis on the order?”
3. Compare the printed price to the direct-purchase prices before deciding how to proceed.

What counts as a “normal” CEA level

Start with the range printed on your own report. Published ranges for CEA exist, they differ by lab, and they change if you smoke.

• Cleveland Clinic says “healthcare providers consider typical CEA levels to be between 0 and 3 ng/mL,” and adds: “If you smoke cigarettes, a normal CEA level may be up to 5 ng/mL.”
• Labcorp’s reference range is 0 to 4.7 ng/mL, with separate limits of under 3.9 ng/mL for a nonsmoker and under 5.6 ng/mL for a smoker.
• MedlinePlus gives no number, but explains the smoking caveat: “If you smoke, you may need to stop for a while before your test. That’s because smoking increases CEA levels.”
• Quest’s directory hides its range until a service area is chosen.

None of the sources we checked gives a treatment target for CEA, so there is no “clinical target” to add here. And the number is not a verdict either way. The National Cancer Institute says “having an elevated level of a tumor marker does not mean that someone has cancer” and that “noncancerous conditions can sometimes cause an increase in the level of a tumor marker”; Cleveland Clinic says “CEA doesn’t tell you whether you have cancer.” In the other direction, NCI says “not everyone with a particular type of cancer will have a higher level of a tumor marker associated with that cancer,” so a CEA inside the range does not rule cancer out.

(Where lab ranges and “optimal” ranges come from, and who decides.)

This page can tell you where those numbers came from. It cannot tell you what yours means; that reading belongs to your doctor, alongside your imaging, your earlier CEA levels, and your history.

Quick questions people ask

What is a CEA test? MedlinePlus says “a CEA test measures how much of a specific protein called carcinoembryonic antigen (CEA) you have.” Medicare’s policy describes it as “a protein polysaccharide found in some carcinomas” that “is effective as a biochemical marker for monitoring the response of certain malignancies to therapy.” The National Cancer Institute lists CEA as a marker for “colorectal cancer and some other cancers.” On billing paperwork it is CPT code 82378.

Is a CEA test a cancer screening test? No. MedlinePlus: “CEA tests are not used to screen for or diagnose cancer.” Cleveland Clinic: “Healthcare providers don’t use these tests to diagnose cancer.” Quest and Labcorp say the same in their directories, and Medicare’s policy never mentions screening. For colorectal cancer, the screening test Medicare covers is the fecal occult blood test, with its own frequency rules.

Does a high CEA mean cancer? Not by itself. NCI says an elevated tumor marker “does not mean that someone has cancer,” and NCI says marker results “are usually combined with the results of other tests, such as biopsies or imaging, to diagnose cancer.” Smoking alone raises CEA, which is why both Cleveland Clinic and Labcorp publish a separate, higher limit for smokers. What your result means is a conversation with your doctor.

Do you have to fast for a CEA test? MedlinePlus says “for a CEA blood test, you usually don’t need to do anything to prepare,” and Quest’s directory lists no patient preparation. The one thing MedlinePlus does flag is smoking: “If you smoke, you may need to stop for a while before your test.” Ask your doctor what they want.

How often will Medicare pay for a CEA test? The policy’s general limits are once per chemotherapy cycle for a metastatic tumor that makes CEA, and every two months after colorectal cancer surgery, with more frequent testing allowed when there has been a significant change in the level or in your condition. For an in situ carcinoma, once, with one repeat if the result is abnormal.

Sources and data dates

Medicare payment amount: CMS Clinical Laboratory Fee Schedule, 2026 Q3 file (national rate for 82378). Coverage rules: CMS Medicare Coverage Database, NCD 190.26 (Carcinoembryonic Antigen), a national policy identical in every state, and the same text in the NCD Manual, Chapter 1, Part 3. Test descriptions, preparation, and ranges: National Cancer Institute (Tumor Markers fact sheet and list), MedlinePlus (CEA Test; Tumor Marker Tests), Cleveland Clinic (CEA Test), Quest test 978, Labcorp test 002139. Consumer prices checked September 2026. Information current as of the date shown above; coverage is always determined by Medicare when your claim is processed.

ClaraCover provides information, not medical, billing, or insurance advice. Talk to your doctor about what tests you need.